After two historic approvals, Editas unveils promising early results for its sickle cell therapy: #ASH23

SAN DIEGO — As its competitors celebrate the landmark approval of two sickle cell gene therapies, Editas Medicine detailed promising early results in a small group of patients for its own gene-edited sickle cell treatment.

Across two studies in sickle cell disease and transfusion-dependent ?-thalassemia, Editas reported that 11 patients…
Click here to view original post